Clinical Trial Update: 177Lu-HTK03170 in mCRPC With PSMA Positive Disease [Phase 1, Phase 2]

View source ↗

Summary

Trial update for a Phase 1/2 study of the radiopharmaceutical 177Lu-HTK03170 in metastatic castration-resistant prostate cancer; recruitment is ongoing by invit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-HTK03170

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION